Cargando…

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

BACKGROUND: Panobinostat is a new agent for the treatment of relapsed and refractory multiple myeloma (rrMM) as part of a combination regimen. This article presents an overview of the mechanism of action, pharmacokinetics, safety, efficacy, patient care strategies, and role of the agent in treating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Redic, Kimberly A, Hough, Shannon M, Price, Erika M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869663/ https://www.ncbi.nlm.nih.gov/pubmed/27274274 http://dx.doi.org/10.2147/OTT.S87962

Ejemplares similares

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms
por: Ma, Yanping, et al.
Publicado: (2017)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
por: San-Miguel, Jesus F., et al.
Publicado: (2016)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
por: Maouche, Nadjoua, et al.
Publicado: (2022)

Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials
por: Gao, Xiao, et al.
Publicado: (2019)

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
por: Liu, Jing-di, et al.
Publicado: (2016)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
por: Zhou, Yu-bo, et al.
Publicado: (2021)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
por: Berdeja, Jesus G., et al.
Publicado: (2021)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
por: Phi, Ji Hoon, et al.
Publicado: (2017)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model
por: Bloudek, Lisa, et al.
Publicado: (2016)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
por: Zheng, Yanhua, et al.
Publicado: (2018)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

OR05-06 Histone Deacetylase Inhibitor, Panobinostat, In Combination With A Smac-mimetic For The Treatment Of Ovarian Granulosa Cell Tumours
por: Chu, Simon, et al.
Publicado: (2023)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_66ehtp9di0jep08m5g6llpqhhg